Alimenté par : Claudia (ADFI Alsace), Gaëlle (ADFI), Isabelle, Maïlé Onfray

Cet outil s'appuie sur PubMind

Un accès direct à la littérature scientifique via la base PubMed permettant de faciliter la veille sur les enjeux complexes de la santé mentale et du fait religieux : de la neuroscience des croyances à l'étude des abus spirituels, en passant par la prise en charge des traumatismes et des processus de déconversion.

Dernière synchronisation le 23/06/2026

Thérapies de Conversion

Pratiques visant à modifier l'orientation sexuelle ou l'identité de genre, illégales en France depuis la loi n°2022-92, et leurs effets psychologiques documentés.

500 articles disponibles

conversion therapy
sexual orientation change effort
SOCE harm
gender identity conversion
reparative therapy mental health
ex-gay therapy
conversion practice religious

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few years, the co…

Thérapies de Conversion
Tang, H., Zhang, W., Cao, J., Cao, Y., Bi, X., Zhao, H., Zhang, Z., Liu, Z., Wan, T., Lang, R., Sun, W., Du, S., Yang, Y., Lu, Y., Zeng, D., Wu, J., Duan, B., Lin, D., Li, F., … Editorial, B. o. a. r. d. . o. f. . t. h. e. . C. h. i. n. e. s. e. . J. o. u. r. n. a. l. . o. f. . H. e. p. a. t. o. b. i. l. i. a. r. y. . S. u. r. g. e. r. y. (2025). Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).. Biosci Trends, 18(6), 505-524. https://doi.org/10.5582/bst.2024.01394
14/01/2025 Lire →

Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma.

Recently, a systemic therapy for advanced hepatocellular carcinoma (HCC) has been developed. The regimen for unresectable HCC varies and includes single or multi-tyrosine kinase inhibitors, monoclonal…

Thérapies de Conversion
Hakoda, H., Ichida, A., & Hasegawa, K. (2025). Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma.. Biosci Trends, 18(6), 525-534. https://doi.org/10.5582/bst.2024.01372
14/01/2025 Lire →

Efficacy of Combined PD-1 Inhibitor and Bevacizumab in Unresectable Liver Metastasis of MSI-H Colorectal Cancer: A Case Report.

BACKGROUND Programmed death 1 (PD-1) inhibitors have demonstrated limited effectiveness in patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC). Recent studies suggest that th…

Thérapies de Conversion
Wang, Q., Zhong, J., Wang, Y., Bao, J., Li, S., & Yang, L. (2025). Efficacy of Combined PD-1 Inhibitor and Bevacizumab in Unresectable Liver Metastasis of MSI-H Colorectal Cancer: A Case Report.. Am J Case Rep, 26, e946757. https://doi.org/10.12659/AJCR.946757
10/01/2025 Lire →

Treatment outcomes and prognostic factors in patients with colorectal cancer and synchronous lung metastases in the conversion therapy era.

PURPOSE: The Japanese Grade Classification based on the status of pulmonary and mesenteric nodal metastases and the presence of extrapulmonary metastases had a prognostic value in patients with colore…

Thérapies de Conversion
Nozawa, H., Suzuki, N., Tsushima, T., Murono, K., Sasaki, K., Emoto, S., Fujishiro, M., Sato, M., & Ishihara, S. (2025). Treatment outcomes and prognostic factors in patients with colorectal cancer and synchronous lung metastases in the conversion therapy era.. Int J Colorectal Dis, 40(1), 9. https://doi.org/10.1007/s00384-024-04799-1
09/01/2025 Lire →

Exploring Social and Structural Determinants of Substance Use Among Sexual and Gender Minority Adults in the United States.

PurposeTo identify key social and structural factors associated with hazardous alcohol and problematic drug use among sexual and gender minority (SGM) adults.MethodsWe conducted a cross-sectional seco…

Thérapies de Conversion
Zhang, C., Tang, Y., Kniffen, W., & Liu, Y. (2025). Exploring Social and Structural Determinants of Substance Use Among Sexual and Gender Minority Adults in the United States.. J Int Assoc Provid AIDS Care, 24, 23259582251409855. https://doi.org/10.1177/23259582251409855
01/01/2025 Lire →

Evaluation of Combined Lipiodol and Epirubicin-Loaded Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.

PURPOSE: To evaluate the short-term clinical efficacy, side effects and risk factors affecting the clinical effectiveness of the combination of lipidol and epirubicin-loaded drug-eluting bead transart…

Thérapies de Conversion
Song, D., Feng, X., Zhou, Y., Cai, Y., & Xue, T. (2025). Evaluation of Combined Lipiodol and Epirubicin-Loaded Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.. J Hepatocell Carcinoma, 12, 2723-2733. https://doi.org/10.2147/JHC.S565056
01/01/2025 Lire →

Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.

BACKGROUND: Conversion therapy provides patients with intermediate-advanced hepatocellular carcinoma (HCC) an opportunity for radical resection, but the prognostic significance of residual tumor in re…

Thérapies de Conversion
Zhang, H., Yang, T., Huang, L., Li, B., Xu, H., & Wei, Y. (2025). Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.. Front Immunol, 16, 1704239. https://doi.org/10.3389/fimmu.2025.1704239
01/01/2025 Lire →

ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?

Thérapies de Conversion
Tsuji, T., Matsuda, S., Sato, Y., Tanaka, K., Sasaki, K., Watanabe, M., Hamai, Y., Nasu, M., Saze, Z., Nakashima, Y., Nomura, M., Yamamoto, S., Booka, E., Ishiyama, K., Bamba, T., Sakanaka, K., Tsushima, T., Takeuchi, H., Kato, K., & Kawakubo, H. (2025). ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?. Ann Surg Oncol, 32(1), 325-326. https://doi.org/10.1245/s10434-024-16310-9
01/01/2025 Lire →

Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.

BACKGROUND: Conversion therapies after immune checkpoint inhibitors (ICIs) plus tyrosine-kinase inhibitors (TKIs) provide curative surgery chance and prolong survival for unresectable hepatocellular c…

Thérapies de Conversion
Jin, Z., Li, X., Lv, L., Zhang, B., Ma, X., Chen, S., You, J., Wu, X., Wang, L., Liu, X., Wang, F., Chen, X., Yu, L., Zhang, S., & Zhang, L. (2025). Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.. J Hepatocell Carcinoma, 12, 1921-1941. https://doi.org/10.2147/JHC.S523476
01/01/2025 Lire →

TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study.

BACKGROUND: Transarterial chemoembolization (TACE) combined with Lenvatinib plus programmed death-1 inhibitor (PD-1 inhibitor) is recommended for unresectable hepatocellular carcinoma (uHCC), and it h…

Thérapies de Conversion
Lu, C., Liu, R., Zhang, Y., Luo, J., Luo, C., Jiang, Z., Huang, M., Qiu, C., & Chen, J. (2025). TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study.. J Hepatocell Carcinoma, 12, 1527-1540. https://doi.org/10.2147/JHC.S517855
01/01/2025 Lire →

Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.

BACKGROUND AND AIMS: Most Hepatocellular carcinoma (HCC) diagnoses occur at advanced stages precluding radical surgical resections. Conversion therapy offers a viable chance for patients with unresect…

Thérapies de Conversion
Wang, Z., Zhang, C., Yin, J., & Li, N. (2025). Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.. Front Immunol, 16, 1451965. https://doi.org/10.3389/fimmu.2025.1451965
01/01/2025 Lire →

Rare Gingival Metastasis Occurring After Conversion Therapy Followed by Resection of Initially Unresectable Hepatocellular Carcinoma: A Case Report.

Gingival metastases from hepatocellular carcinoma (HCC) are exceedingly rare and highly prone to be misdiagnosed without biopsy. Here, we report an initially unresectable HCC patient who received effe…

Thérapies de Conversion
Zhan, J., Huang, H., Zhan, T., Liu, X., & Cheng, Q. (2025). Rare Gingival Metastasis Occurring After Conversion Therapy Followed by Resection of Initially Unresectable Hepatocellular Carcinoma: A Case Report.. J Hepatocell Carcinoma, 12, 705-713. https://doi.org/10.2147/JHC.S514983
01/01/2025 Lire →